Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr
The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
The company is a medical dictation solution used by medical practitioners
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The NFI is published to promote the rational use of medicines in the country.
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Subscribe To Our Newsletter & Stay Updated